Comment on "Drug discovery: Turning the titanic"

Science Translational Medicine

Volumn 6, Issue 229, 2014, Pages

  Lesterhuis, W Joost ^a   Bosco, Anthony ^b   Lake, Richard A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESEARCH; CHEMORADIOTHERAPY; CONTROL STRATEGY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; TREATMENT INDICATION;

ANIMALS; DRUG DISCOVERY; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84899099848     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008763     Document Type: Article

References (10)

1. E. A. Zerhouni, Turning the Titanic. Sci. Transl. Med. 6, 221ed2 (2014).
2. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011).
3. M. Hay, D. W. Thomas, J. L. Craighead, C. Economides, J. Rosenthal, Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40-51 (2014).
4. R. Bernards, A missing link in genotype-directed cancer therapy. Cell 151, 465-468 (2012).
5. H. Kitano, Biological robustness. Nat. Rev. Genet. 5, 826-837 (2004).
6. P. van Hagen, M. C. Hulshof, J. J. van Lanschot, E. W. Steyerberg, M. I. van Berge Henegouwen, B. P. Wijnhoven, D. J. Richel, G. A. Nieuwenhuijzen, G. A. Hospers, J. J. Bonenkamp, M. A. Cuesta, R. J. Blaisse, O. R. Busch, F. J. ten Kate, G. J. Creemers, C. J. Punt, J. T. Plukker, H. M. Verheul, E. J. Spillenaar Bilgen, H. van Dekken, M. J. van der Sangen, T. Rozema, K. Biermann, J. C. Beukema, A. H. Piet, C. M. van Rij, J. G. Reinders, H. W. Tilanus, A. van der Gaast; CROSS Group, Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366, 2074-2084 (2012).
7. S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton, M. Sznol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
8. E. S. Nakasone, H. A. Askautrud, T. Kees, J. H. Park, V. Plaks, A. J. Ewald, M. Fein, M. G. Rasch, Y. X. Tan, J. Qiu, J. Park, P. Sinha, M. J. Bissell, E. Frengen, Z. Werb, M. Egeblad, Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21, 488-503 (2012).
9. D. G. DeNardo, D. J. Brennan, E. Rexhepaj, B. Ruffell, S. L. Shiao, S. F. Madden, W. M. Gallagher, N. Wadhwani, S. D. Keil, S. A. Junaid, H. S. Rugo, E. S. Hwang, K. Jirström, B. L. West, L. M. Coussens, Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54-67 (2011).
10. S. J. Diede, Spontaneous regression of metastatic cancer: Learning from neuroblastoma. Nat. Rev. Cancer 14, 71-72 (2014).